Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

Among 32,542 adults with type 2 diabetes, 581 using GLP-1 receptor agonists and 572 using SGLT2 inhibitors developed dementia during a median 6.3-year follow-up.

• No significant differences in the risk of all-cause dementia were found between users of GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.
• The hazard ratio for all-cause dementia was 1.01, indicating a similar risk for both medication groups.
• Subgroup analyses supported the absence of significant differences in the incidence of vascular and Alzheimer's dementia.
• SGLT2 inhibitor use was not associated with an increased risk of dementia compared to GLP-1 receptor agonists.

AI simplified